CAM
KURA icon

Connacht Asset Management’s Kura Oncology KURA Stock Holding History

Connacht Asset Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-77,501
Closed -$2.19M – 130
2021
Q1 		$2.19M Buy
+77,501
New +$2.45M 0.49% 59

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Connacht Asset Management's KURA Position: Q2 2021 in Review

Connacht Asset Management sold out of Kura Oncology (KURA) in Q2 2021, closing a stake of 77,501 shares — an estimated $2.19M sold.

Connacht Asset Management first reported a position in KURA in Q1 2021 and held it in 1 quarter. The position peaked at $2.19M in Q1 2021. 171 funds tracked by Wall St. Rank hold KURA as of Q2 2021.

  • Connacht Asset Management reported no remaining Kura Oncology position as of Q2 2021 after selling out during the quarter.
  • Connacht Asset Management sold 77,501 Kura Oncology shares in Q2 2021, an estimated $2.19M.
  • Connacht Asset Management first reported a position in Kura Oncology in Q1 2021 and held it in 1 quarter.
  • Connacht Asset Management's Kura Oncology position peaked at $2.19M in Q1 2021.
  • 171 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2021.

Based on Connacht Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.